NEW YORK–(BUSINESS WIRE)–Avoro Ventures, a global venture capital firm investing in life sciences, announced today that Mark Chin has joined the firm as a Partner, focused on its venture capital investment efforts.
Mark has 15 years of healthcare experience across venture capital, strategy consulting, business and corporate development. Prior to joining Avoro Ventures, Mark was a Managing Director at Arix Bioscience focused on private and public biotech investments. During his time at Arix, he sourced and led 10 private biotech investments resulting in 4 IPOs, 2 reverse mergers, and 2 acquisitions. Prior to Arix, Mark was a Principal at Longitude Capital, where he focused on investments in biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group and worked in corporate development at Gilead Sciences and market planning at Genentech.
Mark will be joining Uya Chuluunbaatar, PhD, as an Investment Partner working with Behzad Aghazadeh, PhD, Managing Partner of Avoro Ventures, and Garheng Kong, MD/PhD, Avoro Ventures Advisory Partner.
About Avoro Ventures
Avoro Ventures is an affiliated company of Avoro Capital Advisors, an SEC-registered investment manager based in New York City, with over $4.5 billion in capital primarily focused on life sciences and biotechnology.
